• Sign In
  • FAQ
  • Create an Account
Currency
USD currency flagUSD
Toggle Nav
My Cart
Menu
Account
Settings
Currency
USD currency flagUSD

c-Kit

Items 1-50 of 74

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. A10699
    Pazopanib HCl (GW786034)

    VEGFR/PDGFR/FGFR inhibitor

    Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
    Quick View
  2. A10967
    Vatalanib (PTK787) 2HCl

    VEGFR inhibitor

    Vatalanib (PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis that inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2. CAS: 212141-51-0 (HCl) 212141-54-3 (Free base)
    Quick View
  3. A10101
    Tivozanib (AV-951)

    VEGFR Inhibitor

    Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
    Quick View
  4. A10290
    Dasatinib (BMS-354825)

    Abl-Src inhibitor

    Dasatinib (BMS-354825) is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor. The main targets of dasatinib, are BCR/ABL, Src, c-Kit, ephrin receptors, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2.
    Quick View
  5. A10468
    Imatinib Mesylate

    Bcr-Abl inhibitor

    Imatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway.
    Quick View
  6. A16320
    Dasatinib Monohydrate
    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
    Quick View
  7. A15152
    Masitinib mesylate

    KIT/PDGFR inhibitor

    Masitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
    Quick View
  8. A10502
    Ki8751

    VEGFR-2 inhibitor

    Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays.
    Quick View
  9. A11518
    Pazopanib (GW-786034)

    VEGFR inhibitor

    Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
    Quick View
  10. A10250
    Regorafenib (BAY 73-4506)

    VEGFR inhibitor

    Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
    Quick View
  11. A10996
    XL184 free base (Cabozantinib)

    VEGFR inhibitor

    XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
    Quick View
  12. A11581
    Toceranib (PHA 291639, SU 11654)

    c-Kit, PDGFR, VEGFR inhibitor

    Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
    Quick View
  13. A10259
    Imatinib (Gleevec)

    PDGFR inhibitor

    Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor.
    Quick View
  14. A15520
    Pexidartinib (PLX3397)

    CSF1/Kit/FLT3 inhibitor

    Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
    Quick View
  15. A10558
    Masitinib ( AB1010)

    c-Kit inhibitor

    Masitinib (AB1010) is a protein tyrosine kinase inhibitor.
    Quick View
  16. A10880
    Sunitinib Malate

    RTK inhibitor

    Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
    Quick View
  17. A10103
    Axitinib

    VEGFR inhibitor

    Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).
    Quick View
  18. A11472
    Ki 20227

    M-CSFR, CSF1R inhibitor

    Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R).
    Quick View
  19. A11411
    Dovitinib (TKI-258)

    RTK inhibitor

    Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
    Quick View
  20. A12421
    CHMFL-ABL/KIT-155

    ABL/c-KIT dual kinase inhibitor

    CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor.
    Quick View
  21. A11546
    Regorafenib Hydrochloride

    VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

    Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Quick View
  22. A11556
    SU14813 maleate

    multi-targeted receptor tyrosine kinases inhibitor

    SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
    Quick View
  23. A13530
    Flumatinib mesylate

    c-Abl/c-Kit/PDGRFβ inhibitor

    Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.
    Quick View
  24. A14156
    AZD 2932

    mutil-targeted protein tyrosine kinase inhibitor

    AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
    Quick View
  25. A15933
    AC710

    FLT3/KIT/PDGFRα/PDGFRβ inhibitor

    AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity.
    Quick View
  26. A16246
    AC710 Mesylate

    FLT3/KIT/PDGFRα/PDGFRβ inhibitor

    AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
    Quick View
  27. A16258
    Flumatinib

    multi-kinase inhibitor

    Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRbeta and c-Kit respectively.
    Quick View
  28. A16867
    AZD3229 Tosylate

    pan-KIT mutant inhibitor

    AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
    Quick View
  29. A21503
    Amuvatinib hydrochloride

    multi-targeted tyrosine kinase inhibitor

    Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret.
    Quick View
  30. A19259
    AZD3229

    pan-KIT mutant inhibitor

    AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
    Quick View
  31. A15003
    AST 487

    RET kinase inhibitor

    AST487 is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.
    Quick View
  32. A15062
    DCC-2618

    C-Kit/PDGFR inhibitor

    DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively.
    Quick View
  33. A15182
    N-Desethyl Sunitinib

    VEGFR/PDGFRβ/KIT inhibitor

    N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively).
    Quick View
  34. A15218
    Regorafenib monohydrate

    Tyrosine kinase inhibitor

    Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
    Quick View
  35. A15519
    PLX647

    FMS/KIT inhibitor

    PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.
    Quick View
  36. A17076
    Anlotinib HCl

    RTK inhibitor

    Anlotinib, also known as AL3818, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. CAS: 1058156-90-3 (free base) 1360460-82-7 (HCl)
    Quick View
  37. A17162
    ISCK03

    c-kit inhibitor

    ISCK03 is a potent c-kit inhibitor.
    Quick View
  38. A17567
    Lenvatinib mesylate

    multi-targeted tyrosine kinase inhibitor

    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
    Quick View
  39. A18440
    c-Kit-IN-2

    c-KIT inhibitor

    c-Kit-IN-2 is a c-KIT inhibitor with an IC50 of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1, and 2 nM, respectively.
    Quick View
  40. A18476
    CHMFL-KIT-033

    c-KIT T670I mutant inhibitor

    CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM.
    Quick View
  41. A30311
    Famitinib

    c-kit/VEGFR/PDGFR Inhibitor

    Famitinib is a potent multi-targeted kinase inhibitor that primarily targets c-kit, VEGFR-2, and PDGFRβ, with IC50 values of 2.3 nM, 4.7 nM, and 6.6 nM, respectively. This orally active compound demonstrates significant antitumor activity in human gastric cancer cells and xenograft models. Famitinib also induces apoptosis, making it a valuable tool for research in cancer therapeutics and signaling pathways.
    Quick View
  42. A33597
    Imatinib-d8

    c-Kit Inhibitor

    Imatinib-d8 is a deuterium-labeled derivative of Imatinib, a selective inhibitor targeting c-Kit and other tyrosine kinases, including BCR/ABL, v-Abl, and PDGFR. This compound exhibits potent anti-cancer activity by inhibiting kinase activity, making it a valuable tool for research in oncology and molecular biology. Its deuterium labeling allows for advanced tracking in pharmacokinetic studies and metabolic research.
    Quick View
  43. A33660
    Velzatinib

    c-KIT Inhibitor

    Velzatinib is a selective inhibitor of c-KIT and targets multiple receptor tyrosine kinases including PDGFRB, PDGFRA, CSF1R, FLT3, and LCK. With IC50 values of 2.6 nM for PDGFRB and 44 nM for c-KIT, it demonstrates potent antitumor activity. Velzatinib has shown efficacy in xenograft mouse models, making it a valuable tool for cancer research and drug development targeting dysregulated growth signaling pathways.
    Quick View
  44. A34593
    c-Kit Receptor modulator-1

    c-Kit Receptor Modulator

    c-Kit Receptor modulator-1 is a selective modulator of the c-Kit receptor, primarily involved in cell signaling pathways associated with hematopoiesis and mast cell function. This compound exhibits potent activity against malignancies such as canine mastocytoma, human gastrointestinal stromal tumors, and small cell lung cancer. It is a valuable tool for research focused on tumor biology and therapeutic interventions targeting c-Kit signaling pathways.
    Quick View
  45. A34596
    c-Kit-IN-12

    C-Kit Inhibitor

    c-Kit-IN-12 is a potent inhibitor of the c-Kit receptor with an IC50 value of less than 10 nM in various KIT mutant cell lines, including BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A. This compound is valuable for investigating c-Kit-related pathologies, particularly in cancer research. Its specificity and efficacy make it a useful tool for elucidating the role of c-Kit in oncogenic processes and for exploring potential therapeutic strategies.
    Quick View
  46. A34597
    (S)-c-Kit-IN-12

    C-Kit Inhibitor

    (S)-c-Kit-IN-12 is a potent c-Kit inhibitor, exhibiting an IC50 value of less than 10 nM across four different KIT mutant cell models, including BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A. This compound is suitable for investigating c-Kit-related diseases, particularly in cancer research applications, where dysregulation of c-Kit signaling is implicated.
    Quick View
  47. A34568
    Vimseltinib

    c-FMS(CSF-IR)/c-Kitdual Inhibitor

    Vimseltinib is a selective dual inhibitor of c-FMS (CSF-IR) and c-Kit, demonstrating IC50 values of less than 0.01 μM and 0.1-1 μM, respectively. This compound exhibits robust biological activity, making it a valuable tool for investigating signaling pathways involved in hematopoiesis and various pathologies such as cancer and inflammatory diseases. The oral bioavailability of Vimseltinib enhances its potential for in vivo studies and therapeutic applications.
    Quick View
  48. A34569
    Bezuclastinib

    c-kit Inhibitor

    Bezuclastinib is a highly selective inhibitor of the c-kit tyrosine kinase, demonstrating potent activity against the KIT D816V mutation. This compound is valuable for researching nonadvanced systemic mastocytosis (NonAdvSM) and provides insight into the underlying mechanisms of this condition. Its oral bioavailability makes it a convenient option for in vivo studies targeting c-kit dysregulation.
    Quick View
  49. A34571
    Elenestinib

    Tyrosine Kinase Inhibitor

    Elenestinib is a selective orally active tyrosine kinase inhibitor, demonstrating a potent inhibitory effect on the KIT D816V mutant with an IC50 value of 6 nM. Its mechanism of action is primarily focused on inhibiting aberrant signaling pathways associated with systemic mastocytosis. Due to its limited ability to cross the blood-brain barrier, Elenestinib is particularly applicable in the investigation of hematologic disorders related to mast cell proliferation and activity.
    Quick View
  50. A34572
    c-Kit-IN-5-1

    c-Kit Inhibitor

    c-Kit-IN-5 is a potent c-Kit inhibitor, demonstrating IC50 values of 22 nM in kinase assays and 16 nM in cellular assays. This compound exhibits over 200-fold selectivity for c-Kit compared to other kinases, such as KDR, p38, Lck, and Src. Due to its favorable pharmacokinetic properties, c-Kit-IN-5 is well-suited for research applications exploring c-Kit-related signaling pathways and their implications in various diseases, including cancer.
    Quick View

Items 1-50 of 74

Page
per page
Set Descending Direction
Shop By
Shopping Options